To examine the role of intratympanic Dexamethasone (ITD) in the prevention of Cisplatin-induced hearing loss.
Study Design
Prospective randomized controlled clinical trial.
Setting
Tertiary referral center.
Subjects and Methods
Twenty-six patients suffering from a neoplastic disease for which the treatment protocol included Cisplatin were recruited. Prior to each Cisplatin treatment session ITD was injected to the baseline randomly assigned ear while the other ear of the same patient served as the control. Audiometry and Distortion Product Otoacoustic Emissions (DPOAEs) test results of the baseline and follow-up examinations were compared within and between the study and control ears.
Results
The cumulative dose of Cisplatin was greater than 400 mg for the 15 subjects who completed the study. The pure tone threshold at 8000 Hz and pure tone average threshold at 4000 to 8000 Hz significantly increased in both the study (P < .005, P < .03, respectively) and control ears (P < .01, P < .005, respectively). Significant increase in the pure tone threshold for 6000 Hz was observed in the control (P < .02) but not in the study group. Within the groups comparison also revealed significant decrease in the DPOAE average signal-to-noise ratio (SNR) for the f2 frequencies 7031 (P < .04) and 8391 Hz (P < .04) and SNR average for 4000 to 8000 Hz in the control (P < .04) but not in the study ears.
Conclusions
ITD significantly attenuated hearing loss at 6000 Hz and decreased the outer hair dysfunction in the DPOAE f2 range of 4000 to 8000 Hz. ITD might have potential in the reduction of Cisplatin-induced hearing loss.
RybakLP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg. 2007;15:364-369.
2.
PaksoyMAyduranESanlıAEkenMAydınSOktayZA. The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats. Med Oncol. 2011;28:615-621.
RybakLPMukherjeaDJajooSRamkumarV. Cisplatin ototoxicity and protection clinical and experimental studies. Tohoku J Exp Med. 2009;219:177-186.
5.
SchweitzerVG. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope. 1993;103:1-52.
6.
Benedetti PaniciPGreggiSScambiaG. Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-year survival analysis and neurological follow-up. Int J Gynecol Cancer. 1993;3:44-53.
7.
EianprapaiPYamamotoNHiraumiH. Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients. Laryngoscope. 2012;122:1392-1396.
8.
Konrad-MartinDJamesKEGordonJS. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring. J Am Acad Audiol. 2010;21:301-314.
9.
SchachtJTalaskaAERybakL. Cisplatin and Aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec. 2012;295:1837-1850.
10.
ShupakATalDPrattHSharoniZHochmanA. Attenuation of cerebral oxygen toxicity by sound conditioning. Otol Neurotol. 2004;25:186-192.
11.
WangJLadrechSPujolRBrabetPVanDeWaterTRPuelJL. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res. 2004;64:9217-9224.
12.
AlamSAIkedaKOshimaT. Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res. 2000;141:28-38.
13.
ClericiWJDiMartinoDLPrasadMR. Direct effect of reactive oxygen species on cochlear outer hair cells. Hear Res. 1995;84:30-40.
14.
TsukasakiNWhitworthCARybakLP. Acute changes in cochlear potentials due to cisplatin. Hear Res. 2000;149:189-198.
15.
RybakLPWhitworthCA. Ototoxicity: therapeutic opportunities. Drug Discov Today. 2005;10:1313-1321.
16.
WaissbluthSPitaroJDanielSJ. Gene therapy for cisplatin-induced ototoxicity: a systematic review of in vitro and experimental animal studies. Otol Neurotol. 2012;33:302-310.
17.
GiaccaM. Introduction to gene therapy. In: GiaccaM, ed. Gene Therapy. New York, NY: Springer-Verlag Italia; 2010:1-7.
18.
HargunaniCAKemptonJBDeGagneJMTruneDR. Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form. Otol Neurotol. 2006;27:564-569.
19.
TruneDCanlonB. Corticosteroid therapy for hearing and balance disorders. Anat Rec. 2012;295:1928-1943.
20.
ShimazakiTIchimiyaISuzukiMMogiG. Localization of glucocorticoid receptors in the murine inner ear. Ann Otol Rhinol Laryngol. 2002;111:1133-1138.
21.
DaldalAOdabasiOSerbetciogluB. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg. 2007;137:747-752.
22.
HaakeSMDinhCTChenSEshraghiAAVanDeWaterTR. Dexamethasone protects auditory hair cells against TNFalpha-initiated apoptosis via activation of PI3K/Akt and NFkappaB signaling. Hear Res. 2009;255:22-32.
23.
TopdagMIseriMGelenliE. Effect of intratympanic dexamethasone, memantine and piracetam on cellular apoptosis due to cisplatin ototoxicity. J Laryngol Otol. 2012;126:1091-1096.
24.
ZhangCWengerTMatternJ. Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumorsCancer Biol Ther. 2007;6:278-287.
25.
HerrIUcurEHerzerK. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res. 2003;63:3112-3120.
26.
McCallAASwanEEBorensteinJTSewellWFKujawaSGMcKennaMJ. Drug delivery for treatment of inner ear disease: current state of knowledge. Ear Hear. 2010;31:156-165.
27.
SaltANPlontkeSK. Principles of local drug delivery to the inner ear. Audiol Neurootol. 2009;14:350-360.
28.
PlontkeSKBiegnerTKammererBDelabarUSaltAN. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol. 2008;29:401-406.
29.
StachlerRJChandrasekharSSArcherSM. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. 2012;146:S1-S35.
30.
ShupakATalDSharoniZOrenMRavidAPrattH. Otoacoustic emissions in early noise induced hearing loss. Otol Neurotol. 2007;28:745-752.
31.
BiroKNozsekLPrekoppP. Characteristics and risk factors of cisplatin induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology. 2006;70:177-184.
32.
KnightKRKraemerDFWinterCNeuweltEA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25:1190-1195.
American Speech-Language Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994;36:11-19.
35.
ZuurCLSimisYJWLansdaalPEM. Audiometric patterns in otoxicity of intra-arterial cisplatin chemoradiation in patients with locally advanced head and neck cancer. Audiol Neurotol. 2006;11:318-330.
36.
KumagamiHTerakadoMTakahashiH. Distribution of glucocorticoid receptors and 11a-hydroxysteroid dehydrogenase isoforms in the human inner ear. Otol Neurotol. 2013;34:151-157.
37.
YorgasonJGLuxfordWKalinecF. In vitro and in vivo models of drug ototoxicity: studying the mechanisms of a clinical problem. Expert Opin Drug Metab Toxicol. 2011;7:1521-1534.
38.
UnderwoodJLMurphyCGChenJ. Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Am J Physiol. 1999;277:330-342.
39.
MurphyDDanielSJ. Intratympanic Dexamrthasone to prevent Cisplatin ototoxicity: a guinea pig model. Otolaryngol Head Neck Surg. 2011;145:452-457.
40.
ShaS-HTaylorRForgeASchachtJ. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res. 2001;155:1-8.
41.
ShafikAGElkabarityRHThabetMTSolimanNBKallenyNK. Effect of intratympanic dexamethasone administration on cisplatin-induced ototoxicity in adult guinea pigs. Auris Nasus Larynx. 2013;40:51-60.
42.
LaurellGAnderssonAEngstromBEhrssonH. Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig. Cancer Chemother Pharmacol. 1995;36:83-86.
43.
ChandrasekharSSRubinsteinRYKwartlerJA. Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg. 2000;122:521-528.
44.
WangXFernandezRDellamaryL. Pharmacokinetics of dexamethasone solution following intratympanic injection in guinea pig and sheep. Audiol Neurootol. 2011;16:233-241.
45.
BokemeyerCBergerCCHartmannJT. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77:1355-1362.
46.
JacksonLESilversteinS. Chemical perfusion of the inner ear. Otolaryngol Clin N Am. 2002;35:639-653.
